Bao Yawei, Cheng Yong, Liu Wei, Luo Wenguang, Zhou Peijie, Qian Dong
Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Front Oncol. 2022 Apr 4;12:845346. doi: 10.3389/fonc.2022.845346. eCollection 2022.
Although the synergistic effect of traditional therapies combined with tumor targeting or immunotherapy can significantly reduce mortality, cancer remains the leading cause of disease related death to date. Limited clinical response rate, drug resistance and off-target effects, to a large extent, impede the ceilings of clinical efficiency. To get out from the dilemmas mentioned, bacterial therapy with a history of more than 150 years regained great concern in recent years. The rise of biological engineering and chemical modification strategies are able to optimize tumor bacterial therapy in highest measure, and meanwhile avoid its inherent drawbacks toward clinical application such as bacteriotoxic effects, weak controllability, and low security. Here, we give an overview of recent studies with regard to bacteria-mediated therapies combined with chemotherapy, radiotherapy, and immunotherapy. And more than that, we review the bacterial detoxification and targeting strategies biological reprogramming or chemical modification, their applications, and clinical transformation prospects.
尽管传统疗法与肿瘤靶向治疗或免疫治疗相结合的协同效应可显著降低死亡率,但迄今为止,癌症仍是疾病相关死亡的主要原因。有限的临床缓解率、耐药性和脱靶效应在很大程度上阻碍了临床疗效的提升。为摆脱上述困境,拥有150多年历史的细菌疗法近年来重新受到高度关注。生物工程和化学修饰策略的兴起能够最大程度地优化肿瘤细菌疗法,同时避免其在临床应用中固有的缺点,如细菌毒性作用、可控性差和安全性低。在此,我们概述了近期关于细菌介导疗法与化疗、放疗和免疫治疗相结合的研究。不仅如此,我们还综述了细菌解毒和靶向策略——生物重编程或化学修饰、它们的应用以及临床转化前景。